Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress

Molecular and Cellular Biochemistry

Volumn 330, Issue 1-2, 2009, Pages 1-8

  Murthy, Subramanyam N ^a   Sukhanov, Sergiy ^b   McGee, Jennifer ^a   Greco, Joel A ^a   Chandra, Surabhi ^a   Delafontaine, Patrice ^b   Kadowitz, Philip J ^a   McNamara, Dennis B ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Tulane Center for Cardiovascular Health   (United States)

Author keywords

Balloon catheter injury; Cardiovascular disease; Glargine; I M ratio; IGF 1; Insulin resistance; Intimal hyperplasia; Oxidative stress; Type 2 diabetes

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTANE; INSULIN GLARGINE; INSULIN GLULISINE; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CAROTID ARTERY; CATHETER COMPLICATION; CONTROLLED STUDY; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; MORNING DOSAGE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; STAINING; ZUCKER DIABETIC FATTY RAT;

ANIMALS; BALLOON DILATATION; BLOOD GLUCOSE; CAROTID ARTERY INJURIES; HYPERPLASIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; RATS; RATS, ZUCKER; TREATMENT OUTCOME; TUNICA INTIMA;

RATTUS;

EID: 63849242880     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-009-0094-5     Document Type: Article

References (55)

1. JR Sowers ED Frolich 2004 Insulin and insulin resistance: impact on blood pressure and cardiovascular disease Med Clin North Am 88 63 82 10.1016/S0025-7125(03)00128-7 10.1016/S0025-7125(03)00128-7 14871051 1:CAS:528:DC%2BD2cXhs1WltLo%3D (Pubitemid 38165387)
2. SM Grundy IJ Benjamin GL Burke A Chait RH Eckel BV Howard, et al. 1999 A statement for healthcare professionals from the American Heart Association Circulation 100 1134 1146 10477542 1:STN:280:DyaK1Mvgs1KjsA%3D%3D
3. PWF Wilson JB Meigs 2008 Cardiometabolic risk: a Framingham perspective Int J Obes 32 S17 S20 10.1038/ijo.2008.30 10.1038/ijo.2008.30 1:CAS:528:DC%2BD1cXlslSjtbg%3D (Pubitemid 351671297)
4. AA Jawa VA Fonseca 2005 Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes Cardiol Clin 23 119 138 10.1016/j.ccl.2004.06.001 10.1016/j.ccl.2004.06.001 15694742 (Pubitemid 40203089)
5. DM Nathan PA Cleary JY Backlund SM Genuth JM Lachin TJ Orchard, et al. 2005 Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 2643 2653 10.1056/NEJMoa052187 10.1056/NEJMoa052187 16371630 (Pubitemid 41817713)
6. J Meece 2006 Dispelling myths and removing barriers about insulin in type 2 diabetes Diabetes Educ 32 9S 18S 10.1177/0145721705285638 10.1177/0145721705285638 16439485 (Pubitemid 43206838)
7. Harris SB, Yale JF, Gerstein HC (2007) Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism. Professional conference and annual meeting, Vancouver, British Columbia, 24-27 October 2007
8. A Chaudhuri D Janicke MF Wilson D Tripathy R Garg A Bandyopadhyay, et al. 2004 Anti-inflammatory and profibrinolytic effect of insulin in acute st-segment-elevation myocardial infarction Circulation 109 849 854 10.1161/01.CIR.0000116762.77804.FC 10.1161/01.CIR.0000116762.77804.FC 14757687 1:CAS:528:DC%2BD2cXht1ait78%3D (Pubitemid 38252736)
9. HC Gerstein The ORIGIN Trial Investigators 2008 Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) Am Heart J 155 26 32e6 18082485
10. G Zeng FH Nystrom LV Ravichandran LN Cong M Kirby H Mostowski, et al. 2000 Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells Circulation 101 1539 1545 10747347 1:CAS:528:DC%2BD3cXivVyhtr4%3D
11. J Westerbacka R Bergholm M Tiikkainen H Yki-Jarvinen 2004 Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects Arterioscler Thromb Vasc Biol 24 320 324 10.1161/01.ATV.0000110444.59568.56 10.1161/01.ATV.0000110444.59568.56 14656737 1:CAS:528:DC%2BD2cXnsFCjsw%3D%3D (Pubitemid 38197585)
12. S Mäkimattila H Yki-Järvinen 2002 Endothelial dysfunction in human diabetes Curr Diab Rep 2 26 36 10.1007/s11892-002-0054-x 10.1007/s11892-002-0054-x 12643120
13. H Gaenzer G Neumayr P Marschang W Sturm M Lechleitner B Föger, et al. 2002 Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus Am J Cardiol 89 431 434 10.1016/S0002-9149(01)02266-4 10.1016/S0002-9149(01)02266-4 11835925 1:CAS:528:DC%2BD38XhtVKlu7w%3D (Pubitemid 34142519)
14. C Rask-Madsen N Ihlemann T Krarup E Christiansen L Kober C Nervil Kistorp, et al. 2001 Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease Diabetes 50 2611 2618 10.2337/diabetes.50.11.2611 10.2337/diabetes.50.11.2611 11679442 1:CAS:528:DC%2BD3MXotFGisLw%3D (Pubitemid 33642782)
15. S Vehkavaara S Makimattila A Schlenzka J Vakkilainen J Westerbacka H Yki-Järvinen 2000 Insulin therapy improves endothelial function in type 2 diabetes Arterioscler Thromb Vasc Biol 20 545 550 10669655 1:CAS:528: DC%2BD3cXht1yqsLw%3D
16. SM Haffner 2003 Pre-diabetes, insulin resistance, inflammation and CVD risk Diabetes Res Clin Pract 61 Suppl 1 S9 S18 10.1016/S0168-8227(03)00122-0 10.1016/S0168-8227(03)00122-0 12880690 1:CAS:528:DC%2BD3sXls1Cgs7k%3D (Pubitemid 36918317)
17. A Hishinuma M Majima H Kurabayashi 2008 Insulin resistance in patients with stroke is related to visceral fat obesity and adipocytokines J Stroke Cerebrovasc Dis 17 4 175 180 10.1016/j.jstrokecerebrovasdis.2008.01.004 10.1016/j.jstrokecerebrovasdis.2008.01.004 18589336 (Pubitemid 351853435)
18. M Slawik M Schories BA Busse Grawitz M Reincke KG Peterson 2006 Treatment with insulin glargine does not suppress serum IGF-1 Diabet Med 23 814 817 10.1111/j.1464-5491.2006.01863.x 10.1111/j.1464-5491.2006.01863.x 16842489 1:CAS:528:DC%2BD28XptVKjtr0%3D (Pubitemid 44366083)
19. A Rolla 2008 Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety Am J Med 121 6 Suppl S9 S19 10.1016/j.amjmed.2008.03.022 10.1016/j.amjmed.2008.03.022 18514090 1:CAS:528:DC%2BD1cXosFGmt7o%3D (Pubitemid 351726334)
20. JE Gerich 2006 Postprandial hyperglycemia and cardiovascular disease Endocr Pract 12 Suppl 1 47 51 16627380
21. DS Bell JH O'Keefe P Jellinger 2008 Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 14 112 124 18238751
22. Z Milicevic I Raz SD Beattie 2008 Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia Diabetes Care 31 Suppl 2 S155 S160 10.2337/dc08-s240 10.2337/dc08-s240 18227478 1:CAS:528: DC%2BD1cXis1ajt78%3D
23. CV Desouza SN Murthy J Diez B Dunne AS Matta VA Fonseca, et al. 2003 Differential effects of peroxisome proliferator activator receptor α and γ ligands on intimal hyperplasia after balloon catheter induced vascular injury in Zucker rats J Cardiovasc Pharmacol Ther 8 297 306 10.1177/ 107424840300800407 10.1177/107424840300800407 14740079 1:CAS:528: DC%2BD2cXhtVOnsbs%3D
24. S Park SP Marso Z Zhou F Foroudi EJ Topol AM Lincoff 2001 Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus Circulation 104 815 819 10.1161/hc3301.092789 10.1161/hc3301.092789 11502708 1:STN:280: DC%2BD3Mvls12gtg%3D%3D
25. DB McNamara SN Murthy AN Fonseca CV Desouza PJ Kadowitz VA Fonseca 2009 Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention Can J Physiol Pharmacol 87 1 37 50 10.1139/Y08-098 10.1139/Y08-098 19142214 1:CAS:528: DC%2BD1MXksVGltg%3D%3D
26. T Hofmann G Horstmann I Stammberger 2002 Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits Int J Toxicol 21 3 181 189 10.1080/10915810290096315 12055019 1:CAS:528: DC%2BD38XlsF2jurk%3D (Pubitemid 34803493)
27. S Sukhanov Y Higashi SY Shai C Vaughn J Mohler Y Li, et al. 2007 IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice Arterioscler Thromb Vasc Biol 27 2684 2690 10.1161/ATVBAHA.107.156257 10.1161/ATVBAHA.107.156257 17916769 1:CAS:528:DC%2BD2sXhtlahtLvM (Pubitemid 350158923)
28. K Eckardt C May M Koenen J Eckel 2007 IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts Diabetologia 50 2534 2543 10.1007/s00125-007-0815-9 10.1007/s00125-007-0815-9 17898992 1:CAS:528:DC%2BD2sXht1Kku7jJ (Pubitemid 350060636)
29. M Federici O Porzio D Lauro P Borboni B Giovannone L Zucaro, et al. 1998 Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity J Clin Endocrinol Metab 83 2911 2915 10.1210/jc.83.8.2911 10.1210/jc.83.8.2911 9709968 1:CAS:528:DyaK1cXltlajs7s%3D (Pubitemid 28493797)
30. K Siddle B Ursø CA Niesler DL Cope L Molina KH Surinya, et al. 2001 Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors Biochem Soc Trans 29 513 525 10.1042/BST0290513 10.1042/BST0290513 11498020 1:CAS:528:DC%2BD3MXms1Sltro%3D (Pubitemid 32783649)
31. SA Cooper A Whaley-Connell J Habibi Y Wei G Lastra C Manrique, et al. 2007 Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance Am J Physiol Heart Circ Physiol 293 H2009 H2023 10.1152/ajpheart.00522.2007 10.1152/ajpheart.00522.2007 17586614 1:CAS:528:DC%2BD2sXht1WlurrF (Pubitemid 47605846)
32. D LeRoith S Yakar 2007 Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1 Nat Clin Pract Endocrinol Metab 3 302 310 10.1038/ncpendmet0427 10.1038/ncpendmet0427 17315038 1:CAS:528: DC%2BD2sXjt1Smu7Y%3D (Pubitemid 46310535)
33. JR Sowers M Epstein 1995 Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update Hypertension 26 869 879 7490142 1:STN:280:DyaK28%2FovVymtQ%3D%3D
34. RL Duerr MD McKirnan RD Gim RG Clark KR Chien J Ross Jr 1996 Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat Circulation 93 2188 2196 8925588 1:CAS:528:DyaK28Xkt1emtL8%3D
35. G Lombardi A Colao A Cuocolo S Longobardi C Di Somma F Orio, et al. 1997 Cardiological aspects of growth hormone and insulin-like growth factor-I J Pediatr Endocrinol Metab 10 553 560 9467124 1:STN:280:DyaK1c7ivVWktQ%3D%3D
36. A Tivesten K Caidahl V Kujacic XY Sun T Hedner BA Bengtsson, et al. 2001 Similar cardiovascular effects of growth hormone and insulin-like growth factor-I in rats after experimental myocardial infarction Growth Horm IGF Res 11 187 195 10.1054/ghir.2001.0202 10.1054/ghir.2001.0202 11735233 1:CAS:528:DC%2BD3MXpt12lsbw%3D (Pubitemid 33080818)
37. E Chantelau 1998 Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy Br J Ophthalmol 82 725 730 10.1136/bjo.82.7.725 10.1136/bjo.82.7.725 9924360 1:STN:280:DyaK1M7itlCgtw%3D%3D
38. AL Rosenbloom 2007 Recombinant human insulin-like growth factor I (rhigf-I) and rhigf-I/rhigf-binding-protein-3: new growth treatment options J Pediatr 150 7 11 10.1016/j.jpeds.2006.09.040 10.1016/j.jpeds.2006.09.040 17188604 1:CAS:528:DC%2BD2sXhtVSlsQ%3D%3D (Pubitemid 44937721)
39. AL Rosenbloom 2007 The role of recombinant insulin-like growth factor I in the treatment of the short child Curr Opin Pediatr 19 458 464 10.1097/MOP.0b013e3282094126 10.1097/MOP.0b013e3282094126 17630612 (Pubitemid 47075628)
40. P Pennisi O Gavrilova J Setser-Portas W Jou S Santopietro D Clemmons, et al. 2006 Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus Endocrinology 147 2619 2630 10.1210/en.2005-1556 10.1210/en.2005-1556 16513827 1:CAS:528:DC%2BD28Xlt1Whtb4%3D (Pubitemid 43764594)
41. K Cusi R DeFronzo 2000 Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance J Clin Endocrinol Metab 85 3077 3084 10.1210/jc.85.9.3077 10.1210/jc.85.9.3077 10999789 1:CAS:528:DC%2BD3cXmsVKrurY%3D
42. DR Clemmons AC Moses A Sommer 2005 Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose Growth Horm IGF Res 15 265 274 10.1016/j.ghir.2005.05. 002 10.1016/j.ghir.2005.05.002 16005252 1:CAS:528:DC%2BD2MXntVGms7k%3D (Pubitemid 41093731)
43. M Pendergrass E Fazioni D Collins RA Defronzo 1998 IGF-I increases forearm blood flow without increasing forearm glucose uptake Am J Physiol 275 E345 E350 9688638 1:CAS:528:DyaK1cXlsVCkt70%3D
44. S Vehkavaara H Yki-Jarvinen 2004 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes Arterioscler Thromb Vasc Biol 24 325 330 10.1161/01.ATV.0000113817.48983.c5 10.1161/01.ATV.0000113817.48983.c5 14684428 1:CAS:528:DC%2BD2cXnsFCgtw%3D%3D (Pubitemid 38197586)
45. Epidemiology of Diabetes Interventions, Complications (EDIC) RESEARCH GROUP 1999 Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort Diabetes Care 22 99 111 10.2337/diacare.22.1.99 10.2337/diacare.22.1.99 (Pubitemid 29028305)
46. NM Engel-Nitz S Martin P Sun D Buesching V Fonseca 2008 Cardiovascular events and insulin therapy: a retrospective cohort analysis Diabetes Res Clin Pract 81 97 104 10.1016/j.diabres.2008.02.011 10.1016/j.diabres.2008.02.011 18417242 1:CAS:528:DC%2BD1cXmvFaqs74%3D
47. P Dandona A Aljada P Mohanty H Ghanim W Hamouda E Assian S Ahmad 2001 Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86 7 3257 3265 10.1210/jc.86.7.3257 10.1210/jc.86.7.3257 11443198 1:CAS:528:DC%2BD3MXlt1GjtLk%3D (Pubitemid 32674120)
48. R Shamir N Shehadeh M Rosenblat O Eshach-Adiv R Coleman M Kaplan S Hamoud S Lischinsky T Hayek 2003 Oral insulin supplementation attenuates atherosclerosis progression in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 23 1 104 110 10.1161/01.ATV.0000042232.42883.56 10.1161/01.ATV.0000042232.42883.56 12524232 1:CAS:528:DC%2BD3sXhslM%3D (Pubitemid 36091633)
49. L Kuritzky SE Nelson 2005 Beneficial effects of insulin on endothelial function, inflammation, and atherogenesis and their implications J Fam Pract 54 S7 S9 16021783
50. O Reikerås P Gunnes 1986 Effects of high doses of insulin on systemic haemodynamics and regional blood flows in dogs Clin Physiol 6 129 138 10.1111/j.1475-097X.1986.tb00061.x 10.1111/j.1475-097X.1986.tb00061.x 3514087 (Pubitemid 16127582)
51. J Fingerle A Faulmuller G Muller DF Bowen-Pope MM Clowes MA Reidy, et al. 1992 Pituitary factors in blood plasma are necessary for smooth muscle cell proliferation in response to injury in vivo Arterioscler Thromb 12 1488 1495 1450180 1:STN:280:DyaK3s%2FotFCqtw%3D%3D
52. C Indolfi D Torella L Cavuto 2001 Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats Circulation 103 2980 2986 11413090 1:CAS:528:DC%2BD3MXltlyhtrc%3D
53. E Foster S Zhang AM Kahn 2006 Insulin stimulates arterial neointima formation in normal rats after balloon injury Diabetes Obes Metab 8 348 351 10.1111/j.1463-1326.2005.00513.x 10.1111/j.1463-1326.2005.00513.x 16634996 1:CAS:528:DC%2BD28XkvVaisrw%3D
54. T Kubota N Kubota M Moroi Y Terauchi T Kobayashi K Kamata, et al. 2003 Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury Circulation 107 3073 3080 10.1161/01.CIR.0000070937. 52035.25 10.1161/01.CIR.0000070937.52035.25 12810606 1:CAS:528: DC%2BD3sXksF2ntbc%3D (Pubitemid 36758982)
55. HA Durham GE Truett 2006 Development of insulin resistance and hyperphagia in Zucker fatty rats Am J Physiol Regula Integr Comp Physiol 290 R652 R658 1:CAS:528:DC%2BD28XjtFCnsrw%3D